Nasdaq CopenhagenIFRS · DKK

CS MEDICA a/s

CS MEDICA a/s is a Danish MedTech company founded in 2011 that develops and sells CBD-infused medical device products and cosmetics. Its business combines product development, regulatory progression, and commercialization under one corporate structure, with operations centered in Denmark.

Kysy yhtiöstä
Liikevaihto8,1milj. DKK
+0,0 %v/v
Liikevoitto (EBIT)−12,5milj. DKK
+0,0 %v/v
EBIT-marginaali−154,6%
+0,0 %-yks.v/v
Nettotulos−9,7milj. DKK
+0,0 %v/v

Tilikausi 2024 · muutos edellisvuodesta

Kehitys 2020–2024

−20−1001020milj. DKK2020: 3,2 milj. DKK2020: EBIT −0,18 milj. DKK20202021: 11 milj. DKK2021: EBIT −13 milj. DKK20212022: 1,1 milj. DKK2022: EBIT −18 milj. DKK20222023: 8,1 milj. DKK2023: EBIT −12 milj. DKK20232024: 8,1 milj. DKK2024: EBIT −12 milj. DKK20248,1−12
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: CS MEDICA a/s

Liiketoiminta

Osuus liikevaihdosta
CBD medical devices60 %

Medical device products formulated with CBD for wellness or therapeutic use cases.

CBD cosmetics30 %

Topical cosmetic products containing CBD and related ingredients.

Development services10 %

Internal development, testing, and regulatory work supporting new product launches.

Asiakkaat

CS MEDICA sells to buyers interested in CBD-based consumer health and personal care products, including retail channels and other distribution partners. Its end customers are typically consumers and users seeking topical or device-based CBD products, while the commercial buyer may be a distributor, reseller, or channel partner. Regulatory compliance and product positioning matter because the products sit at the intersection of medtech, cosmetics, and wellness.

Consumer wellness buyers

Buy CBD-based products for personal care, comfort, or wellness use.

Retail and distribution partners

Buy products for resale through shops, web channels, or local distribution.

Regulated channel buyers

Buy compliant products that can be marketed within medical-device or cosmetic rules.

Strategia

CS MEDICA's strategy is centered on developing CBD-infused products through the clinical, regulatory, and launch stages described in its development pathway. The company’s competitive position depends on moving products from concept and feasibility into marketable offerings that can be sold through compliant channels. Building a portfolio across medical-device and cosmetic formats also broadens its addressable market and reduces reliance on a single product type.

Regulatory progressionLyhyt aikaväli

CBD products in medtech and cosmetics need compliance before broad commercialization.

Product commercializationLyhyt aikaväli

Revenue depends on turning developed products into market launches and sales.

Portfolio expansionKeskipitkä aikaväli

A broader portfolio can spread regulatory and demand risk across more products.

Maantiede

The company is based in Denmark and its operating footprint is anchored there. The available report excerpt does not disclose a broader country revenue split, so the business should be viewed as Denmark-centered with potential exposure to export and cross-border distribution as products are commercialized. Geography matters because regulatory approval, labeling, and market access for CBD products can vary significantly by country.

Riskit

The main risks come from regulation, product acceptance, and the complexity of commercializing CBD-related healthcare and cosmetic products. Because the business depends on approvals, labeling, and market access, changes in rules or delays in development can materially slow commercialization. There is also execution risk in converting R&D activity into products that achieve sustained demand through distributors or other channels.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Regulatory restrictions on CBD products1Product development failure2Customer and channel concentration3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Regulatory restrictions on CBD productsVaikutus: KorkeaTodennäköisyys: Korkea

    Sales depend on legal classification, approvals, and country-specific compliance.

    Kohdistuu: Medical devices and cosmetics

  2. Product development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Products must progress through feasibility, R&D, and approval before scaling.

    Kohdistuu: Pipeline products

  3. Customer and channel concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    A small number of distributors or buyers can create revenue volatility.

    Kohdistuu: Commercial sales

Kysy Clarifolta: CS MEDICA a/s

Kirjanpito

Harkinnanvaraiset erät
Development cost accounting

Early-stage product work may be capitalized or expensed depending on IFRS criteria.

Vaikutus: Affects EBIT and the carrying value of intangible assets

Impairment of intangibles

Product pipelines can lose value if commercialization is delayed or unsuccessful.

Vaikutus: Can create non-cash charges and reduce equity

Revenue recognition

Sales timing may depend on shipment, delivery, or distributor terms.

Vaikutus: Affects quarterly comparability and reported growth

Warrants and equity instruments

The report references warrants exercisable at a fixed DKK price.

Vaikutus: May affect diluted share count and equity valuation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

CS Diagnostics Corp.

CSDX · Specialty Cleaning, Polishing and Sanitation Preparations

cbdMD, Inc.

YCBD · Perfumes, Cosmetics & Other Toilet Preparations

Sedana Medical

SEDANA · Health Care

CV Sciences, Inc.

CVSI · Pharmaceutical Preparations

Sionna Therapeutics, Inc.

SION · Pharmaceutical Preparations

InMed Pharmaceuticals Inc.

INM · Pharmaceutical Preparations

Päivitetty: 24.10.2026

CS MEDICA a/s liikevaihto, tulos ja tunnusluvut 2024 – Clarifo